With a new primary endpoint and the disappearance of a trial site, tiny Ritter claims a big clinical victory
Over the last few weeks, tiny LA-based Ritter Pharmaceuticals $RTTR has changed the primary endpoint and recalculated the data for its critical Phase IIb/III study of its sole clinical asset. But on Tuesday evening the cash-strapped nanocap biotech declared a win, triggering a (temporary) surge in its stock price.
If you look at all 368 patients in the study, says Ritter, the top-line results found a 40% response for its lactose intolerance drug RP-G28 and a 31% response for the placebo arm. That was not statistically significant. But…
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.